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The amino-terminal region of actin participates in the binding of myosin subfragment I (Sl) during cross-bridge cycling, thereby assisting in the 
activation of the magnesium-dependent myosin ATPase. Effects of three actin fragments on the magnesium-dependent Sl and acto-SI ATPase 
activities in solution were studied. One of the peptides, containing residues actin 1 44, mimicked the Sl ATPase-activating properties of actin and 
in turn inhibited acto-S I ATPasc both in a concentration-dependent manner. This suggests peptide competition for the actin binding site on myosin. 
The other f’ragments. residues actin 1 IX and X2 119, respectively, had no detectable ffect on Sl- and acto-Sl ATPase activity. 
Actin: S I -ATPasc; Acto-S I -ATPase; Actin peptide 
1. INTRODUCTION 
Identification of the myosin binding site on actin is 
an important step towards an understanding of the 
cvclical actin-mvosin interaction and thus of muscle 
c&traction. Chimical cross-linking experiments [l-3] 
as well as immunological studies [4,5] have given 
evidence that the amino-terminal region of actin is 
capable of binding to myosin. Chemical cross-linking of 
actin to SI resulted in a marked activation of Sl Mg2+- 
ATPase activity [6,7]. These results led to the notion 
that Sl and the smaller, ‘outermost’ N-terminal domain 
of actin [8,9] dock at multiple sites. Interestingly, it was 
reported very recently that a synthetic actin fragment, 
containing residues l-28, slightly activated the Sl Mg”- 
ATPase [lo]. Thus, more detailed information is to be 
expected from studies examining the functional 
properties of actin fragments containing the suggested 
segments to which myosin may bind. 
method relics on the measurement of NADH breakdown which is 
coupled to the ATP turnover in the sample by means of an enzyme 
system containing pyruvate kinase (PK) and lactic dehydrogenase 
(LDH) as well as ATP. NADH and phosphoenolpyruvate (PEP) as 
substrates [12]. 
The published procedure [1 I] was modified as follows. The whole 
sampte is illuminated by a light beam (wave-length about 340 nm) 
which causes the NADH contained in the solution to emit fluorescence 
light (at 470 nm). Illumination is intermittent, short intervals (3 s) of 
tight exposure being followed by larger periods (90 s) with no light. 
This is necessary to minimize photo-bleaching of NADH which, under 
continuous stimulation by light, completely masks fluorescence 
changes as small as those detected in the experiments reported here. 
Using intermittent illumination allows the ATPase reaction to proceed 
without photo-bleaching of NADH during the ‘dark’ periods. The 
intensity of NADH-fluorescence is measured and its time course is 
simultaneously plotted on a chart recorder. The peak values of fluo- 
rescence in the short illuminating intervals show the time course of 
ATPase is linear (Fig. I). 
Two solutions arc prepared for the ATPase measurements, solution 
A containing the substrates and enzymes required for the enzyme- 
coupled assay (ATP, NADH, PEP, PK, LDH), solution B containing 
Sl and, if required, actin and/or one of the actin fragments. One 
OS-PI-microdroplet of each of the two solutions is fixed within the 
light beam and the reaction is initiated by causing the two droplets to 
coalesce. Thus one droplet of I .O pt is formed which is instantaneously 
mixed with a piezo crystal-driven microstirrer. 
In this report the influence of three actin peptides 
containing residues l-44, l-18 and 82-~119, respec- 
tively, on Sl and acto-Sl Mg”-ATPase activities in 
solution is described. The peptide 1-44 activated the Sl 
Mg2”-ATPase and inhibited the acto-Sl Mg2”-ATPase. 
Both effects were concentration-dependent. 
2. MATERIALS AND METHODS 
The experimental solution contains (mM): Imidazole 9.5, dithio- 
threitol (DTT) 0.4, NaN, 0.7, KCI 5.0, MgC&, 0.7, ATP 0.3, PEP t .6, 
NADH 0.5; the content of enzymes is LDH 64.6 U/ml, PK 3 I .3 U/ml; 
PH is 7.0 in all experiments; temperature is kept constantly at 25°C. 
Sl was prepared from rabbit skeletal muscle as described earlier 
[l3]. In all experiments Sl was used at a concentration of 0.1 PM (i.e. 
12.5 ng SI in the probe volume of 1~1). 
ATPase activities were determined by use of the oil-well method for 
time resolved microfluorescence assays described earlier [l Il. The 
C~~rre,spondem address: H. Kbgler, II. Physiologisches Institut, Uni- 
versitiit Heidelberg, Im Neuenheimer Fetd 326, 6900 Heidelberg, Ger- 
many. 
Actin was extracted from rabbit skeletal muscle and purified ac- 
cording to [14]. For measurement of acto-SI ATPase activity actin 
concentrations ranged from 2.0 to 10.2 PM. 
The peptides l-44 and 82-1 I9 were isolated from a CNBr digest of 
actin by gel filtration on Sephadex G-50 followed by ion-exchange 
chromatography using SP Trisacryl. Peptide 1-18 was synthesized by 
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Fig. I. Effect of the actin peptide l-44 on acto-S 1 Mg*‘-ATPase. Time 
course of NADH-fluorescence (see section 2). Concentrations are: SI, 
0.1 PM; actin, 6.0pM. A, without peptide; B, with 16.6pM of peptide 
l-44. 
the solid-state method using FMOC-technology by Alta Bioscience 
(University of Birmingham). It was a-N-terminally acetylated prior to 
deblocking and cleavage from the resin and purified to homogeneity 
on a Vydac C-18 HPLC column. Concentrations of all peptides were 
determined by amino acid analysis after acid hydrolysis. 
For each point of data means and standards errors of the means are 
given (n=6). Values given in the text and in Figs. 2 and 4 are original 
experimental data, values given in Fig. 3 are corrected for basal ATP- 
ase activity values of Sl alone and of peptide-activated Sl, which are 
subtracted from acto-Sl ATPase values. 
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Fig. 2. Influence of actin peptide 1114 on acto-Sl Mg*‘-ATPase. 
Concentrations are: Sl, 0.1 PM; actin, (0) 2.0 PM, (A) 4.0 PM, (B) 
6.0 PM, (+) 10.2 PM. The values given in the figure are original 
experimental data which were not corrected for the basal Sl- and 
peptide-Sl ATPase activity. 
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Fig. 3. Effect of actin peptide 144 on acto-Sl ATPase activity for 
c[actin] = 2.OpM (also included in Fig. 2). Original experimental data 
are compared with values corrected for Sl- and peptide-Sl ATPase 
activities. Actin activation is almost completely inhibited at c[peptide] 
= 16.6 PM. Half-maximal inhibition can be estimated to occur at 
about 6 /IM of peptide l--44. (0) Original data; (’ ,) corrected data. 
3. RESULTS 
3.1. Effect of the uctin fragments on ucto-5’1 M$‘-ATP- 
use activity (Figs. 1-3) 
Acto-Sl Mg*‘-ATPase activity was measured at dif- 
ferent actin concentrations. The experiments were 
repeated with the actin peptide l-44 at concentrations 
of 8.3 ,DM and 16.6 PM. The peptide showed a marked 
inhibition of the acto-Sl ATPase, the effect being con- 
centration-dependent. Higher actin concentrations re- 
quired higher concentrations of peptide l-44 for inhibi- 
tion. At the lowest actin concentration used in these 
experiments (2.0 PM) acto-Sl Mg2’-ATPase was 0.78 2 
0.06,umol ATP.mgSl-‘.min-‘. 8.3 PM of peptide caused 
the ATPase activity to drop to 0.30 +_ 0.01 fin-101 
ATP.mgSl-.‘.min-‘, 16.6 ,uM of peptide led to a further 
decrease to 0.25 + 0.03 pmol ATP.mgS 1 -‘.rnin-l. Thus 
peptide inhibition was 61.5% and 68%, respectively. 
At 10.2 FM of actin acto-Sl Mg2’-ATPase was 3.10 
+ 0.08 pmol ATP,mgSl-‘.min-‘. Addition of 8.3 PM 
and 16.6 PM of peptide l-44 resulted in a decrease of 
ATPase activity to 2.41 + 0.18 pmol ATP,mgS 1-I .min-* 
and 1.52 +_ 0.12 pmol ATP.mgSl-‘,min-‘, correspond- 
ing to an inhibition of 22% and 51%, respectively. For 
low actin concentration (2 PM) half-maximal inhibition 
of acto-Sl Mg”-ATPase was estimated to occur at 
about 6 PM peptide l-44. 
The actin fragment 1-18 had no detectable ffect on 
the acto-Sl Mg*‘-ATPase under the same conditions. 
Also peptide 82-l 19 had no influence (data not shown). 
3.2. Effect on Sl Mg2’-ATPuse activity (Fig. 4) 
Sl Mg2’-ATPase activity was measured at 0.1 PM ~1. 
The actin fragment 144 activated the Mg2”-ATPase of 
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Fig. 4. Influence ofactin pcptides 1 44 and I-18 on Sl Mg”-ATPase. 
Concentration of Sl: 0.1 PM. Filled circles. actin residues 1- 44; open 
circles, actin residues I 18. 
S 1 in a concentration-dependent manner. ATPase of S 1 
alone was 60 & 20 nmol ATP-mgSl’~min~‘. At 8.3 PM 
pcptide Sl ATPase was increased to 130 t 10 nmol 
ATP,mg Sl ‘,min~’ , at 16.6 ,LM of peptide ATPasc was 
200 + 30 nmol ATP.mgSlI’.min~‘. Thus peptide activa- 
tion was 2.2-fold and 3.3-fold, respectively. The peptide 
1 18 on the other hand had no effect on the Sl Mg*+- 
ATPase (Fig. 4), and neither did peptide 82--l 19 (data 
not shown). 
4. DISCUSSION 
In this paper we report that a short actin fragment 
containing the amino terminal residues l-44 of the na- 
tive actin sequence is able to both mimic the activating 
effect of actin on Sl Mg*‘-ATPase and to inhibit acto- 
Sl Mg”-ATPase in a concentration-dependent manner, 
confirming the specificity of its interaction with Sl. The 
activating effect of peptide l-44 on Sl Mg”-ATPase is 
weak in comparison to the activating properties of na- 
tive actin which is able to potentiate Sl Mg*‘-ATPase 
by at least a factor of 200 [15]. This strong activating 
ability of actin however depends on its presence in the 
filamentous F-form. Monomeric G-actin was shown to 
activate Sl Mg*‘-ATPase by only a factor of about 4 
(extrapolation of kinetic data to infinite concentrations 
of G-actin) [16]. As the peptide 144 does not contain 
the residues that by now have been identified as possible 
actin-actin recognition sites [ 17,181, the properties of 
the peptide should be compared to those of monomeric 
G-actin rather than of F-actin. Thus, activation of Sl 
Mg*‘-ATPase by peptide l-44 is about as strong as that 
caused by G-actin. 
A shorter amino terminal actin fragment (res. l-18) 
and another peptide from subdomain 1 of actin (res. 
82-119) have no effect on Sl Mg”-ATPase nor on acto- 
S 1 Mg*‘-ATPase. 
These results demonstrate that the peptide l-44 not 
only binds to but also functionally interacts with Sl 
(which of course requires binding first), thus competing 
with actin for its binding site on myosin. This suggests 
that actin activation of Sl Mg”-ATPase must involve 
at least a portion of actin residues 144. The shorter 
fragment 1-18 of actin, which contains the site to which 
Sl can be covalently crosslinked [1,2], is not sufficient 
to functionally interact with Sl. 
This is not necessarily in contradiction to earlier 
suggestions [1,3,19] that the extreme amino terminal 
segment of actin is important for actin-myosin interac- 
tion. Binding of actin 1-18 to Sl may well occur, but 
this would only be detected in our experimental set-up, 
if its effect were sufficient, over the concentration range 
used, to effect either the Sl- or acto-Sl Mg2’-ATPase 
activity. It may well be that several Sl-binding segments 
of actin have to act cooperatively to achieve this. 
An immunological study showed [4] that antibodies 
directed against actin residues 18-28 are able to dis- 
sociate acto-Sl . This finding supports the idea that the 
actin peptide l-44 contains at least one additional site 
of interaction with myosin that is not contained by the 
shorter actin peptide 1-18. This additional site may be 
located in the segment 18-28 since it was found that an 
actin peptide l-28 slightly activated the Sl Mg”-ATP- 
ase [lo]. 
The effect of the actin peptide l-44 in our study was, 
however, far stronger. There might be two possible ex- 
planations for this behaviour, either there is another site 
of actin myosin interaction contained in the segment 
29-44 of actin, or the conformation of the longer frag- 
ment (actin l-44) is more stable and fits better to the 
actin binding site on myosin than the shorter one (actin 
l-28) in ref. [lo], thus presenting the more adequate 
interface for interaction with myosin. 
Residues l-44 of actin contain all three segments of 
beta-pleated sheet contributed to subdomain 1 of actin 
by the N-terminal part of the protein, according to [8]. 
Residues l-32 belong to subdomain 1, 33-44 to sub- 
domain 2 of actin. Further experiments will have to 
show if residues l-32 are as effective as l-44 in inhibit- 
ing the actin activation of Sl ATPase or if the short 
subdomain 2-segment 33-44 is necessary for the effects 
reported here. 
In any event, the data reported here and elsewhere 
support the notion that actin and myosin dock at multi- 
ple sites and that contact with more than one of these 
is necessary to activate the Sl Mg2’-ATPase. 
Acknowledgements: We thank Dr R.S. Goody for helpful discussion 
of the data and providing Sl and actin and also R. Wojciechowski for 
constructing the instrumentation for fluorescence measurements. This 
work was supported by the Deutsche Forschungsgemeinschaft. 
REFERENCES 
[I] Sutoh, K. (1982) Biochemistry 21, 3654-3661. 
[2] Sutoh, K. (1983) Biochemistry 22, 1579-1585. 
[3] Moir, A.J.G., Levine, B.A., Goodearl, A.J. and Trayer, I.P. 
(1987) J. Muscle Res. Cell Motil. 8, 68-69. 
[4] Mkjean, C., Boyer, M., LabbC, J.P., Marlier, L., Benyamin, Y. 
and Roustan, C. (1987) Biochem. J. 244, 571-577. 
[5] Miller, L., Kalnoski, M., Yunossi, Z., Bulinski, J.C. and Reisler, 
E. (1987) Biochemistry 26, 60646070. 
[6] Mornet, D., Bertrand, R., Pantel, P., Audemard, E. and Kassab, 
R. (1981) Nature 292, 301-306. 
33 
Volume 294, number I,2 FEBS LETTERS December 191~ 
[7] Bertrand, R., Chaussepied, P., Kassab, R., Boyer, M., Roustan, 
C. and Benyamin, Y. (1988) Biochemistry 27, 572885736. 
[8] Kabsch, W., Mannherz, H.G., Suck, D., Pai, E.F. and Holmes, 
KC. (1990) Nature 347, 3744. 
[9] Holmes, K.C., Popp, D., Gebhard, W. and Kabsch, W. (1990) 
Nature 347, 44-49. 
[IO] Van Eyk, J.E., Sbnnichsen, F.D., Sykes, B.D. and Hodges, R.S. 
(1991) in: Peptides as Probes in Muscle Research (J.C. Riiegg, 
e.d.), Springer, Heidelberg, pp. 15-31. 
[I I] Riiegg, J.C. and Wojciechowski, R. (1989) Pfliigers Arch. 414, 
597-599. 
[12] G&h, K. and Wojciechowski, R. (1986) Ptliigers Arch. 407, 552- 
557. 
[I31 Weeds, A.G. and Taylor. R.S. (1975) Nature 257, 54-56. 
[14] Drabikowski, W. and Nowak, E. (1973) Biochim. Biophys. Aa 
328, 470-480. 
[15] Offer, G., Baker, H. and Baker. L. (1972) J. Mol. Biol. 66, 435- 
444. 
[16] Eisenberg, E. and Moos, C. (196X) Biochemistry 7, 1486-1489. 
[17] Johnson, P. and Stockmal. V.B. (1982) Int. J. Biol. Macrornol. 
4, 252-255. 
[18] Sutoh, K. (1984) Biochemistry 23, 1942-1946. 
[19] Das Gupta, G., Whim, J.. Bulinski, J.C. and Reisler, E. (1988) 
Biophys. J. 53, 574a. 
34 
